The CSL Centenary Fellowships for early-mid career medical researchers are high-value awards available to Australians who wish to continue a career in medical research in Australia. Two individual five-year $1.25 million fellowships are awarded each calendar year.
This $25 million program was established by CSL Limited in its Centenary year to support Australia’s best and brightest biomedical researchers—fostering excellence in medical research by supporting mid-career scientists to pursue world-class research at an Australian institution.
The 2021 Fellows will be announced on Thursday 15 October, 2020.
CSL Limited is a global specialty biotechnology company that researches, develops, manufactures and markets products to treat and prevent serious human medical conditions.
Two Australian scientists have each been awarded CSL Centenary Fellowships, valued at $1.25 million over five years, to investigate new ways to fight two of the world’s biggest health challenges: cancer and infectious diseases. The Fellowships will be presented at the Australian Academy for Health and Medical Research Online Scientific Meeting 2020 on Thursday 15 October.
Alisa Glukhova is investigating a fundamental cell communication system that guides the growth of embryos but, when it goes wrong, can contribute to cancer and other diseases.
By determining the structure and shape of the Frizzled protein, she hopes to create a path to new kinds of cancer drugs.
The cells in our body need to be told when to grow, what to become, when to multiply – even when to die.
Si Ming Man is tackling central questions of immunology: how do disease-fighting proteins produced by the immune system recognise pathogens, and how can these natural defence mechanisms be harnessed to fight infectious diseases?
The answers could lead to alternatives to over-used and increasingly ineffective antibiotics, providing new ways to combat multidrug-resistant microbes.
Two Australian scientists have each been awarded AUD$1.25
million CSL Centenary Fellowships over five years to improve treatments for two
of the world’s biggest health challenges: malaria and cancer. The Fellowships
will be presented in Perth at the Australian Academy for Health and Medical
Research Gala Dinner on 10 October.
Dr Kamala Thriemer will use her $1.25 million CSL
Centenary Fellowship to develop and optimise treatment programs against vivax
malaria in SE Asia and the Horn of Africa.
Vivax malaria is the second largest cause of malaria deaths and is hard to treat as the parasite can hide in the liver and re-emerge months later. Her studies have shown that as few as one in ten patients successfully complete the long course of treatment.
Kamala is a public health researcher at the Menzies School
of Health Research in Darwin.
Dan Thomas has developed new ways to identify a cancer’s weakness and target it with personalised treatment. He’s already treating acute myeloid leukaemia patients in Adelaide.
His $1.25 million
CSL Centenary Fellowship will facilitate his return from Stanford University to
the South Australian Health and Medical Research Institute (SAHMRI) and The
University of Adelaide.
Daniel began his academic career with a PhD in haematology
from the University of Adelaide.
Is long term memory stored in DNA, and what does it mean for Alzheimer’s?
Changing the odds from one in 10 for older leukaemia patients
Scientists available for interview.
Two Brisbane scientists have each been awarded an AUD$1.25 million, five-year CSL Centenary Fellowship to further research that aims to help patients beat leukaemia and examine the origins of memory to better understand Alzheimer’s disease.
Professor Geoff Faulkner and Associate Professor Steven Lane are the inaugural Fellows in a $25 million program established by CSL in its centenary year to support Australia’s best and brightest biomedical researchers—fostering excellence in medical research by supporting mid-career scientists to pursue world-class research at an Australian institution.
Professor Geoff Faulkner from the University of Queensland thinks long-term memory might be stored in our brain’s DNA and he’ll test his theory in brains affected by Alzheimer’s.
Today, 85 per cent of children with leukaemia can be cured, but the outlook for patients over 60 is bleak, with only 10 per cent surviving beyond one year as their cancer adapts to weather the storm of standard chemotherapy treatments. Steven wants to change that outlook.
Two Australian scientists have each been awarded an AUD$1.25 million, five-year CSL Centenary Fellowship to further research that aims to help patients beat leukaemia and examine the origins of memory to better understand Alzheimer’s disease.
Professor Geoff Faulkner and Associate Professor Steven Lane are the inaugural Fellows in a $25 million program established by CSL in its centenary year to support Australia’s best and brightest biomedical researchers—fostering excellence in medical research by supporting mid-career scientists to pursue world-class research at an Australian institution.
Geoff Faulkner is testing a bold idea— he thinks long-term memory might be stored in our brain’s DNA. If he’s right, it will revolutionise both our understanding of life’s blueprint and how we manage diseases like schizophrenia and Alzheimer’s.
There’s DNA in every human cell called ‘junk’ or ‘non-coding’ DNA because our bodies don’t use it to generate proteins, the building blocks of life.
The strange thing is, this DNA makes up over 98 per cent of our genome. Surely it must do something. The question is: what?
Geoff Faulkner has been studying this question for years with his team from the MRI-UQ. Now, working with the Queensland Brain Institute (QBI), Geoff’s inaugural CSL Centenary Fellowship will help him delve deeper, using brains bequeathed by Alzheimer’s patients.
Leukaemia is one of Australia’s deadliest types of cancer. However, as Steven Lane knows, it’s not just one type—it’s hundreds of different types, each with its own genetic fingerprint.
This variation means some types of leukaemia are treatable, whereas others quickly develop resistance. Today, 85 per cent of children with leukaemia can be cured, but the outlook for patients over 60 is bleak—only 10 per cent survive beyond one year.
Steven wants to change that outlook. Together with his team at the QIMR Berghofer Medical Research Institute in Brisbane he has developed the capacity to rapidly profile the genetics of leukaemia types and model them in the lab.
We are a specialist science communication and public relations business. We help you communicate complex ideas simply to the public, media, government, and industry; on any platform from social media, to media, pitches, publications, events and conferences.
Our team are all working from home and can consult/train/mentor/write via phone, Zoom, Teams, Skype etc
Indigenous health, shark gonads, blind books, and future food: it’s National Science Week!
Sarah's structure of the course, specific insight and understanding of science, her contacts and common mistakes made in communication were great and furthered my skills in this area.
Anonymous - Sydney Jan 2020
Science In Public
2020-01-28T15:04:28+11:00
Anonymous - Sydney Jan 2020
Sarah's structure of the course, specific insight and understanding of science, her contacts and common mistakes made in communication were great and furthered my skills in this area.
This is one of the best science communication courses I have ever encountered. It teaches all research to think out of box and really simplify their research in lay man's language. I will highly recommend this to anyone looking to learn more about science communication.
Shwathy Ramesh
Science In Public
2020-02-24T09:29:55+11:00
Shwathy Ramesh
This is one of the best science communication courses I have ever encountered. It teaches all research to think out of box and really simplify their research in lay man's language. I will highly recommend this to anyone looking to learn more about science communication.
The CSL Centenary Fellowships for early-mid career medical researchers are high-value awards available to Australians who wish to continue a career in medical research in Australia. Two individual five-year $1.25 million fellowships are awarded each calendar year.
CSL Limited Media Release
Geoff Faulkner is testing a bold idea— he thinks long-term memory might be stored in our brain’s DNA. If he’s right, it will revolutionise both our understanding of life’s blueprint and how we manage diseases like schizophrenia and Alzheimer’s.
Leukaemia is one of Australia’s deadliest types of cancer. However, as Steven Lane knows, it’s not just one type—it’s hundreds of different types, each with its own genetic fingerprint.
